Diopter Technologies Completes Early Clinical Study for Innovative Ocular Surface Disease Treatment
TL;DR
Diopter Technologies' dissolving contact lens offers a competitive edge in treating ocular diseases by actively delivering healing factors, eliminating the need for removal procedures.
Diopter's lens works by releasing growth factors from amniotic-derived materials and dissolving over 48-72 hours, enhancing bioavailability and patient comfort without clinical removal.
This innovative lens from Diopter Technologies promises to improve ocular health globally, offering a less invasive, more effective treatment for various eye conditions.
Diopter Technologies introduces a groundbreaking dissolving contact lens that not only treats eye diseases but also dissolves away, making eye care simpler and more effective.
Found this article helpful?
Share it with your network and spread the knowledge!
Diopter Technologies has reached a significant milestone with the completion of early clinical studies for its dissolving amniotic membrane and biopolymer contact lens, a groundbreaking therapeutic device aimed at treating various ocular surface diseases. This innovative lens is designed to address conditions such as dry eye syndrome, corneal trauma injuries, and post-surgical wounds by releasing growth factors from amniotic-derived materials and dissolving within 48-72 hours, thereby eliminating the need for clinical removal.
The technology behind this lens includes sustained growth factor release, which has been shown to reduce scarring and inflammation while promoting epithelial regeneration. Its self-dissolving design ensures that the biopolymer matrix completely dissolves within 2-3 days, avoiding the risks associated with removal procedures that could disrupt healing tissues. Additionally, the lens offers enhanced bioavailability, delivering growth factors to the ocular surface in a synergistic manner.
Initial clinical study results are promising, with no adverse events reported and an increase in patient comfort over a 48-hour continuous wear period compared to standard silicon hydrogel lenses. Chris Adams, CEO of Diopter Technologies, highlighted the device's ability to actively deliver healing factors, marking a shift from passive coverage to intelligent tissue remodeling in ocular surface rehabilitation.
The device is currently being studied for multiple indications, including chemical/thermal injury recovery, post-refractive surgery care, and chronic dry eye management, with preliminary data indicating potential in these billion-dollar market opportunities. Diopter Technologies plans to launch the product in Q1 2026, following the completion of ongoing human trials and submission of an FDA 510K application. This development represents a strategic expansion of the company's ocular drug delivery portfolio, building on its previous success in demonstrating nine-day intraocular pressure control from a single 50-hour lens wear period in glaucoma models.
Curated from 24-7 Press Release
